Aptevo Therapeutics Inc. (APVO) stock
APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.46−0.09 (-15.97%)
Close on Nov 17, 2026Market cap $830.71KP/E –Yield –
Aptevo Therapeutics cash
Cash and short-term investments held at the end of each period.
Aptevo Therapeutics's cash was $9.80M at Jun 30, 2026. For fiscal 2025 it was $21.62M, up 148.1% from the year before. Over ten years it grew 16.6% a year on average. The highest annual figure on record is $80.78M in fiscal 2017.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.62M | +148.1% |
| FY2024 | Dec 31, 2024 | $8.71M | -48.5% |
| FY2023 | Dec 31, 2023 | $16.90M | -25.3% |
| FY2022 | Dec 31, 2022 | $22.64M | -49.7% |
| FY2021 | Dec 31, 2021 | $45.04M | +12.7% |
| FY2020 | Dec 31, 2020 | $39.98M | +221.2% |
| FY2019 | Dec 31, 2019 | $12.45M | -59.4% |
| FY2018 | Dec 31, 2018 | $30.64M | -62.1% |
| FY2017 | Dec 31, 2017 | $80.78M | +47.1% |
| FY2016 | Dec 31, 2016 | $54.93M | +1084.5% |
| FY2015 | Dec 31, 2015 | $4.64M | +29.1% |
| FY2014 | Dec 31, 2014 | $3.59M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $9.80M | +4.1% |
| Q1 FY2026 | Mar 31, 2026 | $14.53M | +579.1% |
| Q4 FY2025 | Dec 31, 2025 | $21.62M | +148.1% |
| Q3 FY2025 | Sep 30, 2025 | $21.06M | +171.6% |
| Q2 FY2025 | Jun 30, 2025 | $9.41M | +16.7% |
| Q1 FY2025 | Mar 31, 2025 | $2.14M | -79.1% |
| Q4 FY2024 | Dec 31, 2024 | $8.71M | -48.5% |
| Q3 FY2024 | Sep 30, 2024 | $7.75M | -59.4% |
| Q2 FY2024 | Jun 30, 2024 | $8.07M | -61.6% |
| Q1 FY2024 | Mar 31, 2024 | $10.25M | -59.5% |
| Q4 FY2023 | Dec 31, 2023 | $16.90M | -25.3% |
| Q3 FY2023 | Sep 30, 2023 | $19.11M | -13.7% |
| Q2 FY2023 | Jun 30, 2023 | $21.01M | -28.6% |
| Q1 FY2023 | Mar 31, 2023 | $25.33M | -27.6% |
| Q4 FY2022 | Dec 31, 2022 | $22.64M | -49.7% |
| Q3 FY2022 | Sep 30, 2022 | $22.15M | -57.5% |
| Q2 FY2022 | Jun 30, 2022 | $29.43M | -51.3% |
| Q1 FY2022 | Mar 31, 2022 | $34.99M | -39.2% |
| Q4 FY2021 | Dec 31, 2021 | $45.04M | +12.7% |
| Q3 FY2021 | Sep 30, 2021 | $52.12M | +109.0% |
| Q2 FY2021 | Jun 30, 2021 | $60.39M | +694.8% |
| Q1 FY2021 | Mar 31, 2021 | $57.52M | +369.3% |
| Q4 FY2020 | Dec 31, 2020 | $39.98M | +221.2% |
| Q3 FY2020 | Sep 30, 2020 | $24.94M | +41.1% |
| Q2 FY2020 | Jun 30, 2020 | $7.60M | -63.7% |
| Q1 FY2020 | Mar 31, 2020 | $12.26M | -66.9% |
| Q4 FY2019 | Dec 31, 2019 | $12.45M | -59.4% |
| Q3 FY2019 | Sep 30, 2019 | $17.68M | -53.0% |
| Q2 FY2019 | Jun 30, 2019 | $20.96M | -53.1% |
| Q1 FY2019 | Mar 31, 2019 | $37.01M | -40.0% |
| Q4 FY2018 | Dec 31, 2018 | $30.64M | -62.1% |
| Q3 FY2018 | Sep 30, 2018 | $37.64M | -61.1% |
| Q2 FY2018 | Jun 30, 2018 | $44.73M | -8.0% |
| Q1 FY2018 | Mar 31, 2018 | $61.65M | +0.6% |
| Q4 FY2017 | Dec 31, 2017 | $80.78M | +47.1% |
| Q3 FY2017 | Sep 30, 2017 | $96.78M | +59.5% |
| Q2 FY2017 | Jun 30, 2017 | $48.63M | – |
| Q1 FY2017 | Mar 31, 2017 | $61.29M | – |
| Q4 FY2016 | Dec 31, 2016 | $54.93M | – |
| Q3 FY2016 | Sep 30, 2016 | $60.68M | – |
See a number that looks wrong?